- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00946192
Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes
June 4, 2021 updated by: Madhusmita Misra, Massachusetts General Hospital
One aim of this study is to determine changes in body composition and hormones that differentiate athletes who stop getting their periods versus those who continue to get their periods and non-athletes.
The second aim of this study is to determine whether transdermal or oral estrogen (versus no estrogen) is effective in increasing bone density and improving bone microarchitecture in adolescent athletes who are not getting their periods and are thus estrogen deficient.
The investigators hypothesize that transdermal estrogen will be more effective than oral estrogen or no estrogen in improving bone health in amenorrheic adolescent athletes.
Study Overview
Status
Completed
Conditions
Detailed Description
As many as 25% of adolescent and young adult endurance athletes develop amenorrhea, and factors that cause amenorrhea to occur in some, but not all, athletes have not been well characterized.
Recent data indicate the critical importance of a negative energy balance state and leptin in regulating the Hypothalamic-pituitary-gonadal (H-P-G) axis.
However, these factors do not completely account for alterations in this axis, and other contributing factors are unclear.
Our preliminary data indicate the importance of low fat mass and fat related hormones in mediating hypogonadism in young athletes.
This study will confirm these data and determine whether low fat mass and altered levels of adipokines, such as leptin and adiponectin, and hormones regulated by fat mass, such as ghrelin and peptide YY (PYY), determine alterations in LH pulsatility.
A very concerning impact of amenorrhea in athletes is low bone mineral density (BMD).
Preliminary data indicate lower BMD in adolescent athletes with amenorrhea (AA) compared with eumenorrheic athletes (EA) and non-athletic controls.
The high prevalence of AA in adolescents is particularly concerning, because this population is potentially at greater risk as it is actively accruing bone.
Of importance, bone microarchitecture, a better predictor of bone strength than BMD, has not been studied in AA.
Because pubertal increases in estrogen are integral to optimizing peak bone mass, and AA is characterized by hypoestrogenism, this randomized study of transdermal estrogen versus oral estrogen or no estrogen will also examine whether estrogen replacement increases BMD and improves bone microarchitecture in adolescent AA 14-21 years old.
EA and sedentary controls will be followed without intervention for this period.
Despite the prevalent practice of prescribing oral contraceptives in AA, there is a paucity of data regarding benefits of this intervention in teenagers.
Because transdermal estrogen, unlike oral estrogen, does not suppress IGF-1, an important bone anabolic factor, we expect effects of transdermal estrogen to exceed those of oral estrogen or no therapy.
In addition, preliminary data indicate that low fat mass and alterations in fat related hormones may contribute to decreased bone accrual rates in athletes, and will be confirmed in this study.
To summarize, a better understanding of the pathophysiology of reproductive dysfunction is critical to develop therapeutic strategies that will normalize the reproductive axis and bone accrual, and these are the questions that this study aims to answer.
Study Type
Interventional
Enrollment (Actual)
121
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 21 years (ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Females 14-21 years old Note: Our pilot data are reassuring in that young women 18-25 years old with hypothalamic amenorrhea are not adversely affected with estrogen use. In fact, in our prospective study, beneficial effects were observed both in young women 18-25 years old using oral estrogen, and in 14-18 year old adolescent girls using transdermal estrogen. We therefore feel that including girls in the 14-21 year age range will not be hazardous to their bone health. In fact, given the lack of data in this age group, it is important to study younger women and teenagers rather than extrapolate data from studies in adults to this younger population. Hormone dynamics differ in teenagers compared with adults, and bone mass accrual is even more dependent on estrogen and IGF-1 in younger than older women who have already achieved peak bone mass.
- Bone age (BA) >15 years Note: 99% of adult height is achieved at a BA of 15 years, thus estrogen replacement will not result in stunting of height potential after this age. Although we could have chosen to include girls with a BA >14 in this study, we are limiting this to girls with a BA of >15 years. This is because 2% of growth potential persists at a BA of 14 years, versus only 1% at a BA of 15 years (~0.6" of potential height (130)). Thus, to avoid potential stunting of growth potential with estrogen replacement, we have chosen to include girls with BA of > 15 years.
- BMI between 10th-90th percentiles for age.
- Amenorrhea (for AA): absence of menses for > three months (74) within a period of oligomenorrhea (cycle length > six weeks) for >six months, or absence of menarche at >16 years.
- Eumenorrhea (EA and controls): > nine menses (cycle length 21-35 days) in preceding year.
- Non-athlete healthy controls will be eligible if weight bearing exercise activity is less than two hours a week and if they are not participating in organized team sports.
- Endurance athletes Note: severity of low BMD and menstrual dysfunction differ by kind of exercise and activity. For example, runners have a higher prevalence of menstrual irregularity than swimmers and cyclists (131). By limiting enrollment to endurance athletes, we will eliminate variability from the type of activity. Endurance training is defined as > 4 h of aerobic weight-bearing training of the legs or specific endurance training weekly, or > 20 miles of running weekly for a period of > 6 months in the last year.
Exclusion Criteria:
- Other conditions that may affect bone metabolism
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Estrogen Patch
17Beta-estradiol transdermal patch twice weekly application for 12 months
|
100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Other Names:
|
ACTIVE_COMPARATOR: Estrogen Pill
One pill containing estrogen and progesterone taken daily for 21 days followed by placebo pills only for 7 days; regimen repeated for 12 months.
|
Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
Other Names:
|
SHAM_COMPARATOR: Control
Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
|
Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Lumbar Bone Mineral Density
Time Frame: 12 months
|
Change in bone density with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Total Volumetric Bone Mineral Density (Tibia)
Time Frame: 12 months
|
Change in total volumetric bone density at the tibia with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Madhusmita Misra, MD, MPH, Massachusetts General Hospital Pediatric Neuroendocrine Unit and Harvard Medical School
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ackerman KE, Singhal V, Slattery M, Eddy KT, Bouxsein ML, Lee H, Klibanski A, Misra M. Effects of Estrogen Replacement on Bone Geometry and Microarchitecture in Adolescent and Young Adult Oligoamenorrheic Athletes: A Randomized Trial. J Bone Miner Res. 2020 Feb;35(2):248-260. doi: 10.1002/jbmr.3887. Epub 2019 Nov 7.
- Plessow F, Singhal V, Toth AT, Micali N, Eddy KT, Misra M. Estrogen administration improves the trajectory of eating disorder pathology in oligo-amenorrheic athletes: A randomized controlled trial. Psychoneuroendocrinology. 2019 Apr;102:273-280. doi: 10.1016/j.psyneuen.2018.11.013. Epub 2018 Nov 16.
- Singhal V, Ackerman KE, Bose A, Flores LPT, Lee H, Misra M. Impact of Route of Estrogen Administration on Bone Turnover Markers in Oligoamenorrheic Athletes and Its Mediators. J Clin Endocrinol Metab. 2019 May 1;104(5):1449-1458. doi: 10.1210/jc.2018-02143.
- Ackerman KE, Singhal V, Baskaran C, Slattery M, Campoverde Reyes KJ, Toth A, Eddy KT, Bouxsein ML, Lee H, Klibanski A, Misra M. Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial. Br J Sports Med. 2019 Feb;53(4):229-236. doi: 10.1136/bjsports-2018-099723. Epub 2018 Oct 9.
- Baskaran C, Cunningham B, Plessow F, Singhal V, Woolley R, Ackerman KE, Slattery M, Lee H, Lawson EA, Eddy K, Misra M. Estrogen Replacement Improves Verbal Memory and Executive Control in Oligomenorrheic/Amenorrheic Athletes in a Randomized Controlled Trial. J Clin Psychiatry. 2017 May;78(5):e490-e497. doi: 10.4088/JCP.15m10544.
- Ackerman KE, Slusarz K, Guereca G, Pierce L, Slattery M, Mendes N, Herzog DB, Misra M. Higher ghrelin and lower leptin secretion are associated with lower LH secretion in young amenorrheic athletes compared with eumenorrheic athletes and controls. Am J Physiol Endocrinol Metab. 2012 Apr 1;302(7):E800-6. doi: 10.1152/ajpendo.00598.2011. Epub 2012 Jan 17.
- Ackerman KE, Nazem T, Chapko D, Russell M, Mendes N, Taylor AP, Bouxsein ML, Misra M. Bone microarchitecture is impaired in adolescent amenorrheic athletes compared with eumenorrheic athletes and nonathletic controls. J Clin Endocrinol Metab. 2011 Oct;96(10):3123-33. doi: 10.1210/jc.2011-1614. Epub 2011 Aug 3.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 1, 2009
Primary Completion (ACTUAL)
February 1, 2020
Study Completion (ACTUAL)
April 1, 2021
Study Registration Dates
First Submitted
July 22, 2009
First Submitted That Met QC Criteria
July 23, 2009
First Posted (ESTIMATE)
July 24, 2009
Study Record Updates
Last Update Posted (ACTUAL)
June 11, 2021
Last Update Submitted That Met QC Criteria
June 4, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Menstruation Disturbances
- Amenorrhea
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Progestins
- Estradiol
- Ethinyl Estradiol
- Progesterone
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
- Desogestrel
Other Study ID Numbers
- 2009P000353
- R01HD060827-01A1 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exercise-related Amenorrhea
-
Norwegian School of Sport SciencesNational Dairy CouncilCompletedDepression | Exercise Addiction | Perfectionism | Binge Eating | Body Image | Eating Disorder | Resting Metabolic Rate | Dietary Deficiency | Bone Mineral Density, Low, Susceptibility to | Exercise-Related Amenorrhea | Dietary AmenorrheaNorway
-
Massachusetts General HospitalTerminatedHypothalamic Amenorrhea | Idiopathic Hypogonadotropic HypogonadismUnited States
-
Mayo ClinicEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingHypothalamic AmenorrheaUnited States
-
University of Colorado, Colorado SpringsRecruitingAmenorrhea SecondaryUnited States
-
Stephanie B. Seminara, MDRecruitingHypogonadotropic Hypogonadism | Hypothalamic AmenorrheaUnited States
-
University of California, DavisCompletedBreast Feeding | Milk Expression, Breast | Amenorrhea, PostpartumUnited States
-
Imperial College LondonUniversity College, LondonRecruiting
-
TherapeuticsMDTerminated
-
Solvay PharmaceuticalsCompletedSecondary AmenorrheaUnited States
-
Ferring PharmaceuticalsCompletedPrimary Amenorrhea With Hypogonadotropic HypogonadismUnited States, Canada
Clinical Trials on Transdermal 17Beta-estradiol, progesterone
-
Stanford UniversityCompletedOvarian Failure, PrematureUnited States
-
Cedars-Sinai Medical CenterCompletedHypothalamic Amenorrhea | Estrogen Deficiency | Cardiovascular Disease (CVD)United States
-
Massachusetts General HospitalCompletedMenstruation DisturbancesUnited States
-
Eastern Virginia Medical SchoolWichita State UniversityUnknownFollicle Stimulating Hormone Glycosylation | Urinary FSH21/FSH24 Ratio | Estradiol EffectUnited States
-
Northwestern UniversityUniversity of WashingtonCompletedCardiovascular Disease | Menopause | Postmenopause | PremenopauseUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSuicidal IdeationUnited States
-
Johns Hopkins UniversityCystic Fibrosis FoundationRecruitingCystic Fibrosis | HypoestrogenismUnited States
-
University of Illinois at ChicagoRecruitingSuicidal IdeationUnited States
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedPerimenopausal DepressionUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)RecruitingMenopause | Irritable MoodUnited States